Trials / Completed
CompletedNCT00159770
Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients
Tolerability, Safety, And Efficacy Of Ziprasidone (80 - 160 Mg/D) Versus Olanzapine (10 - 20 Mg/D), Risperidone (4 - 8 Mg/D) Or Quetiapine (300 - 750 Mg/D) In Pretreated Patients With Schizophrenia, Schizoaffective Disorder Or Schizophreniform Disorders - A 12-Week Open-Label, Multicenter Clinical Trial.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 290 (planned)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of the antipsychotic efficacy and safety of ziprasidone versus olanzapine, risperidone or quetiapine in patients with schizophrenia, schizoaffective and schizophreniform disorders under naturalistic conditions of clinical practice
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ziprasidone versus olanzapine , risperidone or quetiapine | |
| BEHAVIORAL | Panss , CGI-C, UKU-SERS-Pa | |
| PROCEDURE | Blood tests |
Timeline
- Start date
- 2001-11-01
- Completion
- 2004-09-01
- First posted
- 2005-09-12
- Last updated
- 2021-02-21
Locations
43 sites across 4 countries: Denmark, Finland, Iceland, Switzerland
Source: ClinicalTrials.gov record NCT00159770. Inclusion in this directory is not an endorsement.